Cosmetic peptide mechanisms — copper-binding, MC1R/MC4R agonism, and topical vs injected delivery

This thread covers the mechanisms of cosmetic and aesthetic peptides in more depth than the Overview piece. Unlike most peptide categories where everything works through one receptor family, this category has genuinely different mechanisms across the compounds in it. Understanding the mechanism difference is the key to understanding why the protocols and route-of-administration choices vary so much within this category.

GHK-Cu — what the research suggests it does.
GHK is a tripeptide (glycine-histidine-lysine) that binds copper(II) ions with high affinity. The bioactive species is the copper-bound complex GHK-Cu — uncomplexed GHK and free copper ions individually do not reproduce the effects of the complex. Endogenous GHK is present in human plasma at levels around 200 ng/mL in young adults and declines with age, with concentrations roughly halved by age 60.

The proposed mechanisms involve multiple downstream effects. Copper-mediated transcriptional effects appear to upregulate expression of genes involved in tissue remodeling, including matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). This rebalancing of the MMP/TIMP system is thought to drive the observed skin remodeling effects — turnover of damaged extracellular matrix and replacement with newer matrix.

GHK-Cu also has documented anti-inflammatory effects and upregulates synthesis of decorin, a small proteoglycan involved in collagen organization. The hair follicle effects appear to involve direct stimulation of follicle dermal papilla cells, with the mechanism still being characterized.

The "copper" in copper peptide is not incidental. The copper ion itself is biologically active in its complexed form — copper is a cofactor for multiple enzymes including lysyl oxidase (involved in collagen and elastin crosslinking) and cytochrome c oxidase. The GHK-Cu complex appears to deliver bioavailable copper to tissues in a way that supports these copper-dependent processes.

Melanocortin receptor agonists — what the research suggests they do.
The melanocortin receptor family has five members (MC1R through MC5R), and they are expressed in different tissues with different downstream effects when activated.

MC1R is expressed primarily in melanocytes (the cells that produce melanin) and activation drives melanin synthesis. This is the receptor that produces the pigmentation effects from melanotan compounds.

MC2R is expressed in the adrenal cortex and binds ACTH (adrenocorticotropic hormone) — not relevant to the cosmetic peptide research.

MC3R and MC4R are expressed in the central nervous system and are involved in appetite and energy balance regulation. MC4R activation also affects sexual arousal pathways.

MC5R is expressed in sebaceous glands and other tissues with effects on lipid secretion.

Melanotan I (afamelanotide) is more selective for MC1R. The pigmentation effects are the primary observed outcome and the side effects on appetite and sexual function are minimal because the central nervous system melanocortin receptors are not significantly activated.

Melanotan II is non-selective across MC1R, MC3R, MC4R, and MC5R. This means it produces pigmentation effects (MC1R) but also produces effects on appetite suppression (MC3R/MC4R), sexual function modulation (MC4R), and sebaceous gland activity (MC5R). The non-selectivity is why melanotan II has a broader and sometimes more disruptive side effect profile than melanotan I.

PT-141 (bremelanotide) is more selective for MC4R. The sexual function effects are the primary application; pigmentation effects from MC1R activation are minimal at typical research dosing.

Hair-loss-targeted peptides — what the research suggests they do.
The hair loss research with peptides centers on the Wnt signaling pathway, which plays a key role in hair follicle development and cycling. Conventional hair loss treatments (finasteride, minoxidil) work through different mechanisms — finasteride through 5-alpha-reductase inhibition affecting androgen metabolism, minoxidil through vasodilation and potassium channel effects.

PTD-DBM is a peptide that has been studied for Wnt pathway modulation effects on hair follicles. The proposed mechanism involves disruption of the CXXC5-Dishevelled interaction, which activates Wnt signaling and promotes hair follicle regeneration. The published research base is younger and thinner than for the established treatments, and the mechanism is still being characterized in detail.

GHK-Cu has separate hair follicle effects through the copper-mediated mechanisms described above. Some research has investigated combination protocols with GHK-Cu and conventional hair loss treatments, leveraging the different mechanisms.

The half-life landscape.
Half-life data for cosmetic peptides is more variable across compounds and less standardized than for the GLP-1 or GH peptide categories.

• GHK-Cu (topical): not really characterized as a plasma half-life because the route is local. The compound is taken up into skin tissues and the local effects persist.
• GHK-Cu (injected): short plasma half-life, on the order of minutes to hours by available estimates, with downstream tissue effects persisting longer.
• Melanotan I: approximately 30 minutes plasma half-life, with pigmentation effects persisting for weeks because melanin production continues after the compound is gone.
• Melanotan II: approximately 30 minutes to 1 hour plasma half-life.
• PT-141: approximately 2 hours plasma half-life.
• PTD-DBM (topical): not characterized as plasma half-life because the route is local.

Topical versus injected — the route question.
The route of administration choice in this category depends on the compound and the research goal.

GHK-Cu studied for skin or hair endpoints is typically topical because the local tissue effects are what is being investigated. GHK-Cu studied for systemic effects (wound healing in non-skin tissues, etc.) is typically injected. The topical research is much larger than the injected research for cosmetic applications.

Melanotan I and II are injection-only for systemic pigmentation effects. The peptides do not absorb effectively through skin or mucous membranes at concentrations that produce systemic effects. Vendors selling oral or topical melanotan for tanning purposes are selling product that does not match the published research base.

PT-141 is studied as both injection and intranasal. Intranasal bioavailability is decent for this compound, which is unusual among the cosmetic peptides.

PTD-DBM and related hair-loss peptides are studied as topical scalp applications. The local follicle effects are what is being investigated, and the systemic absorption is incidental.

Practical takeaway.
The mechanism diversity across this category drives the protocol variety. Copper-mediated tissue effects (GHK-Cu) work topically for skin and hair targets. Melanocortin agonism (melanotan, PT-141) requires injection for systemic effects and the receptor selectivity profile drives the side effect profile. Hair-loss peptides target follicle-specific signaling pathways and are typically topical. Understanding which mechanism is at work in any specific protocol is essential for evaluating the protocol design.

If you want to go deeper into specific compound applications, the related threads in this category cover those topics — the GHK-Cu skin thread, the collagen-versus-GHK-Cu thread, the melanotan II thread, and the PTD-DBM hair loss thread.